

For immediate release



Spiral laminar flow is the predominant flow pattern in 97% of patients in observational study

Dundee, UK, 19 November, 2015 – [Vascular Flow Technologies](#) (VFT), the medical device company using proprietary Spiral Laminar Flow™ (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, has presented data showing that spiral laminar flow is the predominant flow pattern in arteries. ‘*Spiral Laminar Flow in Arteries*’ is one of a number of studies highlighting the advantages of SLF™ technology being presented at the 42nd Annual VEITH Symposium which is taking place in New York between 17-21 November.

While the existence and benefits of spiral flow in the circulatory system was established by Stonebridge and Brophy in 1991, the current study suggests that SLF is the predominant flow pattern in the arteries. The presence of SLF was assessed at 11 arterial sites in 42 volunteers with colour flow Doppler. The incidence of SLF at each of these 11 sites ranged from 81% to 90%. Analysis on the basis of volunteer rather than examination site showed 41 patients out of the 42 in the cohort (97%) had more arterial sites with SLF than without.

VFT uses Spiral Laminar Flow™ (SLF™) technology in its vascular implants to promote longevity and patency of the implant and improve patient outcomes. A helical formation incorporated as a ridge or groove in the implant serves to induce a spiral pattern of blood flow through the implant, replicating the natural spiral laminar flow observed in healthy vessels. The study, led by Graeme Guthrie, suggests that the flow pattern induced by VFT’s SLF™ technology has the potential to replicate natural blood flow in the majority of patients, for cardiovascular diseases at a variety of arterial sites.

Bill Allan, CEO of Vascular Flow Technologies commented: “The results of this observational study is further evidence that SLF™ technology has the potential to reduce the risk of complications post implantation for a wider range of patients”.

ENDS

Notes to Editors

About Vascular Flow Technologies

Vascular Flow Technologies is a leading innovator focused on the research, development and commercialisation of devices to improve blood flow in compromised or diseased blood vessels utilising its proprietary Spiral Laminar Flow™ (SLF™) technology. Natural blood flow has a distinctive singular spiral flow pattern and the patented SLF™ technology is the only clinically-proven design to replicate this.

VFT has two CE marked and FDA approved devices commercialised in Europe and the US, the Spiral Flow™ peripheral bypass (PV) graft and the Spiral Flow™ arteriovenous access (AV) graft. The SLF™ technology is used to create a longer lasting graft or stent, producing a better quality of life for the patient due to reduced vascular complications and improved longevity of the implant.

VFT is a privately held company with headquarters in Dundee, UK.

Further information is available at www.vascular-flow.com.

About Spiral Laminar Flow

Turbulent blood flow near the area where the graft and the blood vessel are sewn together damages the cell lining in the patient's blood vessel wall and causes cell tissue growth (neointimal hyperplasia) which can result in vessel blockage. Spiral Laminar Flow™ technology generates a spiral flow within the graft, reducing turbulence at the point the blood leaves the graft and enters the patient's blood vessel. Vascular Flow Technologies' SLF™ technology is supported by numerous clinical studies and a significant patent array.

For more information, please contact:

Bill Allan

CEO, Vascular Flow Technologies

Telephone: +44 (0) 1382 598 532

Email: info@vascular-flow.com

For media enquiries, please contact:

Gemma Howe

Instinctif Partners

Telephone: +44 207 866 7860

Email: VFT@instinctif.com